XML 40 R50.htm IDEA: XBRL DOCUMENT v2.4.0.8
Summary of Revenue Recognized under Agreement with GSK (Detail) (USD $)
In Thousands, unless otherwise specified
 3 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended
Dec. 31, 2013
Sep. 30, 2013
Jun. 30, 2013
Mar. 31, 2013
Dec. 31, 2012
Sep. 30, 2012
Jun. 30, 2012
Mar. 31, 2012
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2013
National Institutes of Health
Dec. 31, 2012
National Institutes of Health
Dec. 31, 2011
National Institutes of Health
Dec. 31, 2008
Glaxo, Smith, Kline
Dec. 31, 2013
Glaxo, Smith, Kline
Dec. 31, 2012
Glaxo, Smith, Kline
Dec. 31, 2011
Glaxo, Smith, Kline
Dec. 31, 2013
Astra Zeneca
Dec. 31, 2012
Astra Zeneca
Dec. 31, 2011
Astra Zeneca
Dec. 31, 2013
National Institute Of Allergy And Infectious Diseases
Dec. 31, 2012
National Institute Of Allergy And Infectious Diseases
Dec. 31, 2011
National Institute Of Allergy And Infectious Diseases
Product Information [Line Items]                                                
Initial payment                             $ 10,000 $ 1,702 $ 1,428 $ 1,428 $ 720 $ 720 $ 120      
Milestone revenue                     12,000             15,000 2,507 2,462 642      
Total revenues 2,847 2,927 3,392 2,085 1,806 2,874 2,684 2,350 11,251 9,714 21,614         1,702 1,428 16,428 3,227 3,182 762      
Grant revenue                 $ 5,138 $ 3,939 $ 3,110 $ 1,035 $ 368 $ 380               $ 4,103 $ 3,571 $ 2,730